Plasma Adenosine Deaminase Enzyme Reduces with Treatment of Pulmonary Tuberculosis in Nigerian Patients: Indication for Diagnosis and Treatment Monitoring
Emneord (Nøkkelord):
Tuberculosis Patients, Biomarkers, Chemotherapy, LymphocytesSammendrag
Summary: Tuberculosis(TB)-specific host biomarkers for diagnosis and monitoring of treatment response have been identified as priorities for TB research. Macrophage and T cell lymphocytes play vital roles in Mycobacterium tuberculosis immune response and their associated biomarkers could form good candidates for diagnosis and treatment monitoring. The enzyme adenosine deaminase (ADA) is produced mainly by monocytes and macrophages and increase in biological fluids in the course of infection with microorganisms infecting macrophages. This study comprised sixty-eight (68) participants; twenty-four (24) multi-drug-resistant TB(MDR-TB) patients, twenty-four (24) drug-sensitive TB patients(DS-TB) and twenty (20) non-TB apparently healthy individuals. Five (5) milliliters of blood was drawn before commencement of chemotherapy and 6 anti-TB therapy. In DSTB and MDR-TB patients before commencement of chemotherapy and 6 months of anti-TB treatment, the mean plasma levels of ADA were significantly increased compared with control. At 6 months of anti-TB chemotherapy of DSTB or MDR TB patients, ADA level was significantly decreased compared with before chemotherapy. Plasma ADA in DSTB patients before and 6 months of chemotherapy were not significantly different compared MDR TB patients. Plasma ADA level is a promising biomarker for the screening and treatment monitoring of pulmonary tuberculosis but not to differentiate MDR TB from DSTB patients.
Referanser
Adekambi T, Ibegbu CC, Cagle S, Kalokhe AS, Wang YF, Hu Y, Day CL, Ray SM, Rengarajan J (2015). Biomarkers on patient T cells diagnose active tuberculosis and monitor treatment response. J Clin Invest 125(5): 1827-1838.
Afrasiabian S, Mohsenpour B, Bagheri KH, Sigari N, Aftabi K (2013). Diagnostic value of serum adenosine deaminase level in pulmonary tuberculosis. J Res Med Sci 18(3):252-254.
Alexander PE and De P (2007). The emergence of extensively drug-resistant tuberculosis (TB): TB/HIV coinfection, multidrug-resistant TB and the resulting public health threat from extensively drug-resistant TB, Globally and in Canada. Can J Infect Dis Med Microbiol 18(5): 289-291. Basile JI, Geffner LJ, Romero MM, Balboa L, Garcia CS, Ritacco V, Garcia A, Cuffre M et al (2011). Outbreaks of Mycobacterium Tuberculosis MDR strain induce high IL 17 T-cell response in patients with MDR tuberculosis that is closely associated with high antigen burden. J Infect Dis 204(7):1054-1064.
Blackburn MR, Datta SK, Kellems RE (1998). Adenosine deaminase-deficient mice generated using a two-stage genetic engineering strategy exhibit a combined immunodeficiency. J Biol Chem 273: 5093-5100.
Bloom CI, Graham CM, Berry MPR, Rozakeas F, Redford PS et al, (2013). Transcriptional blood signatures distinguish pulmonary tuberculosis, pulmonary sarcoidosis, pneumonias and lung cancers. PLoS One. 8(8): e70630.
Boonyagars L and Kiertiburanakul S (2010). Use of adenosine deaminase for the diagnosis of tuberculosis. A review. J Infect Dis Antimicrob Agents 27:111-118.
Cardoso FLL, Antas PRZ, Milagres AS, Geluk A, Franken KLMC, Oliveira EB, Teixeira HC, Nogueira SA et al (2002). T-cell responses to the Mycobacterium tuberculosis-specific antigen ESAT-6 in Brazilian tuberculosis patients. Infect Immun 70(12):6707-6714.
Çimen F, Çiftçi TU, Berktafl BM, Sipit T, Hoca NT, Dulkar G (2008). The relationship between serum adenosine deaminase level in lung tuberculosis along with drug resistance and the category of tuberculosis. Turk Respir J. 9:20–3.
Edem VF and Arinola OG (2015). Innate cellular Immunity in newly diagnosed tuberculosis patients and during chemotherapy. Annals of Global Health, 81(5):669-674.
Ernst JD (2012). The immunological life cycle of tuberculosis. Nature Rev Immunol 12:581-591.
Giblett ER, Anderson JE, Cohen F, Pollara B, Meuwissen HJ (1972). Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. The Lancet. 300(7786):1067-1069.
Greco S, Girardi E, Masciangelo R, Capoccetta GB, Saltini C (2003). Adenosine deaminase and interferon gamma measurements for the diagnosis of tuberculous pleurisy: a meta-analysis. Int J Tuberc Lung Dis 7: 777–786.
Jacobson MA and Bai TR (1997). Purinergic Approaches in Experimental Therapeutics, eds Jacobson KA, Jarvis MF (Wiley-Liss, Inc. Danvers, MA). pp 585–59.
Keeler E, Perkins MD, Small P, Hanson C, Reed S, Cunningham J, et al (2006). Reducing the global burden of tuberculosis: the contribution of improved diagnostics. Nature 444 (Suppl 1): 49-57.
Liu X, Kim CN, Yang J, Jemmerson R, Wang X (1996). Indeuction of apoptotic program in cell-free extracts: Requirement for dATP and cytochrome c. Cell 86 (1): 147-157.
Olah ME and Stiles GL (1995). Adenosine receptor subtypes: characterization and therapeutic regulation. Annu Rev Pharmacol Toxicol. 35:581-606.
Piras MA, Gakis C, Budroni M, Andreoni G (1978). Adenosine deaminase activity in pleural effusions: An aid to differential diagnosis. Br Med J. 2:1751–1752.
Rozot V, Patrizia A, Vigano S, Mazza-Stalder J, Idrizi E, et al (2015). Combined use of mycobacterium tuberculosis-specific CD4 and CD8 T-cell responses is a powerful diagnostic tool of active tuberculosis. Clin Infect Dis 60 (3):432-437.
Shore A, Dosch HM, Gelfand EW (1981). Role of adenosine deaminase in the early stages of precursor T cell maturation. Clin Exp Immunol 44: 152-5.
Srinivasa RK, Kumar HA, Rudresh BM, Srinivas T, Bhat KH. A comparative study and evaluation of serum adenosine deaminase activity in diagnosis of pulmonary tuberculosis. Biomedical Research 2010 (2):189-194.
Storla DG, Yimer S, Bjune GA (2008). A systematic review of delay in the diagnosis and treatment of tuberculosis. BMC Public Health. 8:15.
Swami KK (2016). Diagnostic and prognostic significance of pleural fluid adenosine deaminase estimation in relation to tuberculosis. Ind J Appl Res. 6(1): 232-233.
Wallis RS, Doherty TM, Onyebujoh P, Vahedi M, Laang H, Olesen O, Parida S, Zumla A (2009). Biomarkers for tuberculosis disease activity, cure and relapse. Lancet Infect Dis 37(3):162-172. Wilkinson RJ, Vordermeier HM, Wilkinson KA, Sjölund A, Moreno C, Pasvol G, Ivanyi J. 1988. Peptide-specific T cell response to Mycobacterium tuberculosis: clinical spectrum, compartmentalization, and effect of chemotherapy. J Infect Dis 178:760-768.
World Health Organization (2006). Diagnostic and
Treatment Delay in Tuberculosis. World Health Organization, Regional Office for the Eastern Mediterranean. 2006:21.
World Health Organization (2011). Guidelines for the programmatic management of drug-resistant tuberculosis, 2011 Update, WHO, Geneva, Switzerland.
World Health Organization (2015). Global Tuberculosis report 2015. WHO, Geneva, Switzerland.
Zavialov AV, Gracia E, Glaichenhaus N, Franco R, Zavialov AV, Lauvau G (2010). Human adenosine deaminase 2 induces differentiation of monocyte and stimulates proliferation of T helper cells and macrophages. J Leukoc Biol 88:279-290.
Nedlastinger
Publisert
Utgave
Seksjon
Lisens
Dette verket er lisensiert under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
